SecSonar.com

Ovid Therapeutics Inc. (OVID)

Ovid Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Ovid Therapeutics Inc. (OVID) is a Biotechnology company based in US with a market capitalization of $360M. Revenue grew 1181.3% year-over-year and free cash flow was negative at -$38.3M. This page tracks OVID's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 23 employees · IPO May 5, 2017

Valuation

Valuation & price

$2.63 · as of May 17, 2026 · -11.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

2.76

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.91$1.64$0.37Jul 25Dec 25Jun 26Jul 7, 25$0.37Jul 9, 25$0.44Jul 11, 25$0.41Jul 15, 25$0.37Jul 17, 25$0.48Jul 21, 25$0.61Jul 23, 25$0.70Jul 25, 25$0.62Jul 29, 25$0.54Jul 31, 25$0.50Aug 4, 25$0.50Aug 6, 25$0.51Aug 8, 25$0.51Aug 12, 25$0.55Aug 14, 25$0.84Aug 18, 25$0.93Aug 20, 25$0.95Aug 22, 25$1.03Aug 27, 25$1.26Aug 29, 25$1.28Sep 3, 25$1.33Sep 5, 25$1.23Sep 9, 25$1.24Sep 11, 25$1.25Sep 15, 25$1.28Sep 17, 25$1.16Sep 19, 25$1.21Sep 23, 25$1.26Sep 25, 25$1.41Sep 29, 25$1.40Oct 1, 25$1.37Oct 3, 25$1.84Oct 7, 25$1.67Oct 9, 25$1.74Oct 13, 25$1.58Oct 16, 25$1.57Oct 20, 25$1.65Oct 22, 25$1.61Oct 24, 25$1.63Oct 28, 25$1.49Oct 30, 25$1.37Nov 3, 25$1.38Nov 5, 25$1.33Nov 7, 25$1.32Nov 11, 25$1.35Nov 13, 25$1.20Nov 17, 25$1.30Nov 19, 25$1.28Nov 21, 25$1.40Nov 25, 25$1.50Nov 28, 25$1.78Dec 2, 25$1.56Dec 5, 25$1.67Dec 9, 25$1.57Dec 11, 25$1.65Dec 15, 25$1.56Dec 17, 25$1.48Dec 19, 25$1.47Dec 23, 25$1.81Dec 26, 25$1.78Dec 30, 25$1.63Jan 2, 26$1.76Jan 6, 26$1.76Jan 8, 26$1.73Jan 12, 26$1.61Jan 14, 26$1.65Jan 16, 26$1.57Jan 21, 26$1.64Jan 23, 26$1.69Jan 28, 26$1.55Jan 30, 26$1.56Feb 3, 26$1.55Feb 5, 26$1.45Feb 9, 26$1.58Feb 11, 26$1.59Feb 13, 26$1.42Feb 18, 26$1.46Feb 20, 26$1.47Feb 24, 26$1.51Feb 26, 26$1.65Mar 2, 26$1.66Mar 4, 26$1.68Mar 6, 26$1.91Mar 10, 26$2.13Mar 12, 26$2.01Mar 16, 26$1.95Mar 19, 26$2.30Mar 23, 26$2.55Mar 25, 26$2.40Mar 27, 26$2.30Mar 31, 26$2.22Apr 2, 26$2.20Apr 7, 26$2.56Apr 9, 26$2.88Apr 13, 26$2.79Apr 15, 26$2.76Apr 17, 26$2.91Apr 21, 26$2.85Apr 23, 26$2.68Apr 27, 26$2.69Apr 29, 26$2.69May 1, 26$2.79May 5, 26$2.83May 8, 26$2.80May 12, 26$2.87May 14, 26$2.80May 18, 26$2.41May 20, 26$2.39May 22, 26$2.47May 27, 26$2.54May 29, 26$2.73Jun 2, 26$2.40Jun 4, 26$2.48Jun 8, 26$2.36Jun 10, 26$2.28Jun 12, 26$2.30Jun 16, 26$2.36Jun 18, 26$2.27Jun 23, 26$2.32Jun 29, 26$2.55
$0.3752-week range$2.96
Loading valuation history…

Fundamentals

Key fundamentals

$360M

Market cap

1181.3%

Revenue growth (YoY)

95.9%

Gross margin

-$38.3M

Free cash flow (USD)

-$56.2M

Net debt

Net cash position

4.0%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$12.6MFY 2021$208.4MFY 2022$1.5MFY 2023$392.0KFY 2024$566.0KFY 2025$7.3M
$0$7.3M

Free cash flow by year

2016 → 2025

FY 2016$-18.0MFY 2017$-31.5MFY 2018$-45.9MFY 2019$-51.3MFY 2020$-52.0MFY 2021$118.4MFY 2022$-56.6MFY 2023$-45.9MFY 2024$-56.0MFY 2025$-38.3M
-$18M-$38.3M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 202595.9%
100.0%95.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 11, 2026Filing
  • 8-K eventDirector AppointmentJun 3, 2026Filing
  • 8-K eventBusiness Updates and Financial ResultsMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing
  • FinancingSecurities RegistrationApr 21, 2026Filing
  • 8-K eventWarrant ExpirationApr 20, 2026Filing

Questions

Frequently asked questions

What is Ovid Therapeutics Inc.'s market cap?

Ovid Therapeutics Inc. (OVID) has a market capitalization of $360M.

What is OVID's P/E ratio?

A meaningful P/E ratio is not available for OVID — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is OVID's price-to-book (P/B) ratio?

OVID trades at 2.76 times book value per share.

Are insiders buying OVID stock?

SEC Form 4 filings show no open-market insider buys at Ovid Therapeutics Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

KROS

Keros Therapeutics, Inc.

$361.9M

IRD

Opus Genetics, Inc.

$364.7M

PBYI

Puma Biotechnology, Inc.

$364.7M

RGNX

REGENXBIO Inc.

$365.2M

CLLS

Cellectis S.A.

$354.5M

PALI

Palisade Bio, Inc.

$366.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.